Published in Clinical Trials Week, June 4th, 2007
The placement was completed at $0.53 per share, a 16% discount to Avexa's volume weighted average share price for the 10 days to 14 March 2007, the day before the Company's shares were placed in trading halt pending announcement of the results of its Phase IIb trial for apricitabine (ATC). Passport Management LLC USA, was the leading...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.